MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies.

Area of Science:

• Neuroscience
• Genetics
• Epigenetics

Background:

• Rett syndrome is a severe neurodevelopmental disorder primarily affecting females.
• It stems from mutations in the methyl-CpG-binding protein 2 (MECP2) gene on the X chromosome.
• MECP2 is crucial for transcriptional regulation, synaptic development, neuronal maturation, and brain's epigenetic regulation.

Purpose of the Study:

• To comprehensively understand Rett syndrome by summarizing MECP2's molecular structure and mutation-specific pathogenesis.
• To elucidate MECP2's regulatory roles in chromatin remodeling, RNA splicing, and miRNA processing.
• To discuss current and future therapeutic strategies for Rett syndrome.

Main Methods:

• Literature review and synthesis of existing research on MECP2.
• Analysis of MECP2's function in gene expression and epigenetic regulation.
• Compilation of data on abnormal phenotypes associated with MECP2 dysfunction.

Main Results:

• MECP2 mutations lead to diverse pathological mechanisms affecting gene expression.
• MECP2 dysfunction causes abnormal phenotypes across various brain regions and other tissues.
• The study provides a detailed overview of MECP2's multifaceted roles in the nervous system.

Conclusions:

• Understanding MECP2's diverse functions and pathological mechanisms is key to developing targeted therapies.
• Current and future therapeutic approaches include AAV-based gene therapy, RNA editing, X chromosome reactivation, and pharmacological interventions.
• This research lays the foundation for advancing Rett syndrome treatment.